TTNP

Titan Pharmaceuticals (TTNP)

About Titan Pharmaceuticals (TTNP)

Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. Its lead product is probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.

Details

Daily high

$3.75

Daily low

$3.68

Price at open

$3.63

52 Week High

$14.80

52 Week Low

$3.03

Market cap

3.4M

Dividend yield

0.00%

Volume

4,081

Avg. volume

46,107

P/E ratio

-.54

Titan Pharmaceuticals News